Phase 4
Completed N=16
Renal and Hormonal Effects of Pioglitazone
Source: ClinicalTrials.gov NCT01090752 ↗Enrolled (actual)
16
Serious AEs
—
Results posted
Apr 2010
Primary outcomePrimary: Effects of Pioglitazone on Renal Hemodynamics — 68.0; 62.4 ml/min/1.73m2
Summary
This study examines the effects of pioglitazone on renal sodium handling in subjects prone to insulin resistance, i.e. diabetic and/or hypertensive subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effects of Pioglitazone on Renal Hemodynamics |
68.0; 62.4 | — |
| PRIMARY Effects of Pioglitazone on Sodium and Lithium Clearances |
1.05; 1.18 | — |
| PRIMARY Effects of Pioglitazone on 24h Blood Pressure Control |
128; 129 | — |
| SECONDARY Effects of Pioglitazone on Salt Sensitivity |
— | — |
Eligibility Criteria
Inclusion Criteria
- Type II Diabetes
- Hypertension
Exclusion Criteria
- Cardiac or renal diseases
- Anaemia
- Drugs like aspirin, non steroidal anti-inflammatory drugs and hormonal replacement therapy.
Data sourced from ClinicalTrials.gov (NCT01090752). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.